IDSA: Clostridioides difficile 2021 Focused Update

Zusammenfassung

Abstract This clinical practice guideline is a focused update on management of Clostridioides difficile infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for the treatment of CDI. This guideline was developed by a multidisciplinary panel representing the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA). This guideline is intended for use by healthcare professionals who care for adults with CDI, inc

Kerninformationen

upon available resources. Vancomycin remains an acceptable alternative. II. In Patients With Recurrent CDI Episode(s), Should Fidaxomicin Be Used Rather Than Vancomycin? Recommendation : I. In patients with recurrent CDI episodes, we suggest fidaxomicin (standard or extended-pulsed regimen) rather t...

), bezlotoxumab should be reserved for use when the benefit outweighs the risk.” Background Since publication of the 2017 Clinical Practice Guidelines for Clostridioides (formerly Clostridium ) difficile infection (CDI) [ 1 ], new relevant evidence has emerged for treatment options in the mana...

our previous recommendations on treatment of an initial CDI episode and treatment of a first recurrent CDI episode. The other recommendation is a new recommendation for use of an adjunctive treatment agent for CDI. These new recommendations are also included in an updated table from the previous gui...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen